Creech 1982.

Methods	STUDY DESIGN: Parallel study LOCATION, NUMBER OF CENTRES: DURATION OF STUDY: September 1978 to October 1979 CONCEALMENT OF ALLOCATION: D DESCRIBED AS RANDOMISED: Yes DESCRIBED AS DOUBLE BLIND: No METHOD OF RANDOMISATION WELL‐DESCRIBED/APPROPRIATE: Not described METHOD OF BLINDING WELL‐DESCRIBED/APPROPRIATE: Not described DESCRIPTION OF WITHDRAWALS/DROP‐OUTS: Yes GRADE ASSESSMENT QUALITY RATING: Moderate TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT
Participants	INCLUSION CRITERIA: Each patient had to be refractory to standard chemotherapy; have measurable or evaluable disease; an Eastern Cooperative Oncology Group performance status of 0 to 2; a white blood cell count >= 4000/mm3, a platelet count >= 100,000/mm3, a BUN <= 25 mg/100 mL, a creatinine < 1.5 mg/100 mL, and a bilirubin <= 2.0 mg/100 mL. All patients gave informed written consent prior to participation in this study. EXCLUSION CRITERIA: N SCREENED: 73 (58 evaluable) N RANDOMISED: 58 (cisplatin ‐ 21; maytansine ‐ 19; chlorozotocin ‐ 18) N COMPLETED: ASSESS STAGE: No (N LIMITED): (N EXTENSIVE): M: F: AGE:
Interventions	TYPE: Chemotherapy REGIMENS: Cisplatin ‐ 75 mg/m2 intravenous (IV) Cisplatin every 21 days after adequate hydration and diuresis. Maytansine ‐ maytansine 1.5 mg/m2 IV every 21 days. Chlorozotocin ‐ chlorozotocin 120 mg/m2 IV every 42 days. Each drug was given until there was clinical evidence of progressive disease, after which patients were not eligible for treatment with the other study drugs. CO‐INTERVENTIONS:
Outcomes	OUTCOMES MEASURED: Tumour response Survival Toxicity FOLLOW UP ASSESSMENT POINTS: OUTCOMES INCLUDED IN ANALYSES: Tumour response Survival Toxicity
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) Participants	Unclear risk	Not reported
Blinding (performance bias and detection bias) Investigators	Unclear risk	Not reported
Blinding (performance bias and detection bias) Survival	Unclear risk	N/A
Blinding (performance bias and detection bias) Tumour Response	Unclear risk	Not reported
Blinding (performance bias and detection bias) Toxicity	Unclear risk	N/A
Blinding (performance bias and detection bias) Quality of Life	Unclear risk	N/A
Incomplete outcome data (attrition bias) Survival	Unclear risk	N/A
Incomplete outcome data (attrition bias) Tumour Response	High risk	Reasons for withdrawals, drop‐outs and exclusions not reported
Incomplete outcome data (attrition bias) Toxicity	Unclear risk	N/A
Incomplete outcome data (attrition bias) Quality of Life	Unclear risk	N/A
Selective reporting (reporting bias)	High risk	No mention of survival ‐ an expected outcome
Other bias	Low risk	Adequate